Group 1 - The article discusses the monitoring of stock trading activities that exhibit significant abnormal fluctuations, particularly focusing on large buy or sell orders within a one-minute timeframe during continuous bidding phases [1] - The exchange will closely monitor trading behaviors related to stocks that show severe abnormal volatility within ten trading days following the occurrence [1] Group 2 - A list of stocks under abnormal fluctuation monitoring is provided, including their monitoring start and end dates, as well as the dates when the fluctuations began [2] - Specific stocks mentioned include "南方路机," "西藏旅游," "幸福蓝海," and "*ST苏吴," among others, with varying monitoring periods [2]

Group 1 - The average stock price of A-shares is 12.23 yuan, with 42 stocks priced below 2 yuan, the lowest being *ST Suwu at 1.24 yuan [1] - Among the low-priced stocks, 14 are ST stocks, accounting for 33.33% of the total [1] - The Shanghai Composite Index closed at 3559.95 points as of August 1 [1] Group 2 - In the low-priced stock category, 17 stocks increased in price today, with *ST Xingguang, Shanying International, and Zhongtai Automobile leading with increases of 4.86%, 3.17%, and 2.58% respectively [1] - Conversely, 18 stocks decreased in price, with *ST Suwu, *ST Tianmao, and Greenland Holdings showing declines of 5.34%, 4.58%, and 2.59% respectively [1] - The table lists various low-priced stocks along with their latest closing prices, daily price changes, turnover rates, and industry classifications [2]

● 7月31日当日，公司股价开盘跌停后盘中突然大幅上涨，股价波动大。经核实，公司不存在应披露未 披露事项。考虑到公司大额资金被占用尚未解决、AestheFill代理权不确定性、重大违法退市风险等， 公司股价可能存在进一步下跌风险。敬请广大投资者理性投资、审慎决策，切勿盲目跟风炒作，避免因 公司股价波动造成投资损失。 ● 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司股票将被终止上市。根据《上 海证券交易所股票上市规则》第9.5.7条、第9.5.8条，如公司后续收到行政处罚决定书，显示公司触及重 大违法类强制退市情形，公司将申请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的5 个交易日内，向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上市规则》 的相关规定，作出是否终止公司股票上市的决定。 ● 公司将全力配合中国证监会的相关工作，并积极行使听证或进行陈述、申辩等合法权利，维护公司和 广大投资者权益，最终结果以中国证监会出具的正式处罚决定为准。敬请广大投资者关注后续公告并注 意投资风险。 一、公司股票可能被实施重大违法强制退市风险暨立案调查进展情况 公司于2025年 ...

可能被实施重大违法强制退市的第四次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 一、公司股票可能被实施重大违法强制退市风险暨立案调查进展情况 公司于 2025 年 2 月 26 日收到中国证监会《立案告知书》（证监立案字 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督管理委员 会立案告知书暨风险提示公告》（公告编号：临 2025-007）。 （处 罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公司、中吴贸易发 展(杭州)有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限 公司等多家关联公司开展无商业实质的贸易业务，虚增营业收入、营业成本和利 润。上述行为导致*ST 苏吴在 2020 年至 2023 年年度报告中分别虚增营业收入 露营业收入的 26.46%、26.39%、21.26%、16.82%；分别虚增营业成本 48,068.05 万元、44,823.70 万元、41,082.09 万元 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-079 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第四次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载。公司股票已于 2025 年 7 月 14 日起被叠加实施重大违法类强制退市风险警示。 7 月 31 日当日，公司股价开盘跌停后盘中突然大幅上涨，股价波动大。 经核实，公司不存在应披露未披露事项。考虑到公司大额资金被占用尚 未解决、AestheFill 代理权不确定性、重大违法退市风险等，公司股价 可能存在进一步下跌风险。敬请广大投资者理性投资、审慎决策，切勿 盲目跟风炒作 ...

Market Overview - The "童颜针" (youthful needle) has become a popular choice among medical beauty consumers, with a price range of 15,000 to 20,000 yuan per injection, providing effects that can last for about two years. The market size in China is expected to exceed 3.2 billion yuan by 2025, with a compound annual growth rate (CAGR) of over 54% [1][12][17] - The product is primarily composed of poly-L-lactic acid (PLLA), which stimulates collagen production in the skin, leading to improved elasticity and contour [3][4][12] Competitive Landscape - Companies are fiercely competing for exclusive distribution rights, leading to legal disputes. For instance, Jiangsu Wuzhong is involved in a legal battle with Aimeike over the exclusive rights to the product "艾塑菲" (Aesthefill) [12][14] - New Oxygen, a company previously struggling, saw its stock price increase fourfold after selling low-priced youthful needles, indicating a significant market response [1][15] Consumer Behavior - The demand for youthful needles has surged, with reports of nearly 30 inquiries per day at some clinics. However, there are also negative consumer experiences, including adverse reactions and dissatisfaction with results [8][9][12] - The market is seeing a shift in consumer demographics, with younger generations, including those born in the 2000s, increasingly seeking medical beauty treatments [17][19] Industry Trends - The medical beauty industry in China is projected to grow from nearly 300 billion yuan in 2024 to over 400 billion yuan by 2025, with a notable increase in male consumers [17][19] - Major companies, including JD Health, are entering the medical beauty space, offering lower-priced services to attract consumers, which may lead to a more competitive and regulated market [18][19] Product Development - The introduction of new products like youthful needles reflects changing consumer preferences towards less invasive treatments. The industry is expected to continue evolving with new offerings that cater to these preferences [16][17] - The competition is not only about product offerings but also about the speed of research and development, distribution capabilities, and resilience against regulatory risks [17]

Group 1 - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) is facing the risk of being delisted due to significant violations, as indicated in a recent announcement [1] - The China Securities Regulatory Commission (CSRC) issued a notice confirming that the company inflated its revenue, costs, and profits, leading to false records in annual reports from 2020 to 2023 [1][2] - If the formal penalty decision confirms the violations, the company will apply for a trading suspension and disclose relevant information promptly [1] Group 2 - The company failed to accurately disclose its actual controller, with a change in control occurring in February 2018, where Qian Qunshan became the actual controller instead of Qian Qunying as reported [2] - Multiple subsidiaries of the company engaged in non-commercial trade activities with related parties, inflating revenue and profits by nearly 100 million yuan, resulting in false records in annual reports [2] - The company did not disclose significant non-operating fund occupation by related parties in its annual reports from 2020 to 2023, leading to major omissions [2]

Core Viewpoint - The unilateral termination of the exclusive agency rights for AestheFill by Regen has dealt a severe blow to Jiangsu Wuzhong, which is already struggling on the brink of delisting [1][4]. Group 1: Company Impact - The loss of AestheFill is critical for Jiangsu Wuzhong, as it contributed 326 million yuan to revenue in 2024, accounting for 20.42% of total revenue, and 269 million yuan to gross profit, representing 34.80%, leading to a net profit increase of 197.97% [3]. - In Q1 2025, AestheFill's revenue contribution surged to 35.55%, with gross profit share rising to 45.77%, making it the company's primary performance pillar [4]. - Jiangsu Wuzhong has indicated that the medical aesthetics segment's revenue and profit will "significantly decline" in the second half of the year due to this loss [4]. Group 2: Legal and Public Response - In response to the crisis, Jiangsu Wuzhong has initiated legal proceedings, asserting that there was no transfer of agency rights and that the agreement does not include clauses for termination due to administrative penalties [5]. - The company has publicly criticized Regen and Aimeike for "maliciously trampling on contractual spirit" and damaging the image of Chinese enterprises abroad, using unusually strong language [5]. Group 3: Industry Dynamics - The dispute highlights the inherent challenges within the medical aesthetics agency model, where brand owners maintain control, leaving agents in a passive position [6]. - This incident may increase insecurity among the agency group in the industry, potentially leading to reduced market investment and negatively impacting the overall performance of the medical aesthetics supply chain [6]. - The competition in the medical aesthetics market is intensifying, with the market size for facial rejuvenation products in China nearing 600 million yuan in 2023, and a product launch wave expected in 2024 [7].

New Stock Listings - HanGao Group listed on July 30, 2025, with an issue price of 15.43[1] - *ST Zitian and *ST Suwu are under severe abnormal fluctuations as of July 30, 2025[1] - Tianlu Convertible Bonds listed on July 30, 2025, with a risk warning[1] Market Alerts - Multiple stocks including *ST Xinchao and *ST Yuancheng are flagged for severe abnormal fluctuations on July 30, 2025[1] - New listings include companies like Xianghe Precision and Shenshui Planning, with announcements made on July 30, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1] Trading Insights - The report highlights the importance of monitoring newly listed stocks for potential volatility and investment opportunities[1] - Investors are advised to review the latest announcements and risk warnings associated with these stocks to make informed decisions[1]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is experiencing significant stock price fluctuations, with a cumulative decline of over 12% in closing prices over three consecutive trading days, indicating severe abnormal trading conditions [2][4]. Group 1: Stock Trading Abnormalities - The company's stock has shown a cumulative closing price decline of over 12% across three trading days (July 25, July 28, July 29, 2025) [4]. - The stock has exhibited four instances of the same directional abnormal fluctuation within ten trading days, qualifying as severe abnormal trading conditions as per Shanghai Stock Exchange regulations [4]. Group 2: Financial Reporting Issues - The company's 2024 annual financial report received a disclaimer of opinion from the auditing firm, triggering a risk warning for delisting under the Shanghai Stock Exchange rules [3]. - Internal controls over the financial report were also flagged, with related parties of the controlling shareholder identified as having non-operational fund occupation issues [3]. Group 3: Regulatory Actions - On July 13, 2025, the company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for inflating revenue and profits in annual reports from 2020 to 2023, which may lead to mandatory delisting [11]. - The stock has been under a delisting risk warning since July 14, 2025, pending the CSRC's final decision [11]. Group 4: Operational Status - The company has confirmed that, aside from disclosed matters, there have been no significant changes in its daily operations or external environment [5]. - No undisclosed major events, such as asset restructuring or significant business collaborations, have been identified [7]. Group 5: Other Relevant Information - The company is facing potential revenue and profit declines in its medical aesthetics segment due to a termination notice received from Regen Biotech Inc. regarding exclusive agency rights [13]. - As of July 22, 2025, all shares held by the controlling shareholder are under judicial pledge or freeze, indicating potential liquidity issues [13].